Developing the Clinic of the Future, Cloud DX work to be supported by Sheridan College through federal grant
News in Summary
Cloud DX(TSX.V:CDX) (OTCQX:CDXFF) a leading Canadian provider of virtual care and remote patient monitoring solutions is pleased to announce the extension of its remote patient monitoring and virtual care contract with a large Canadian Provincial Health Authority.1
This new agreement extends Cloud DX's original contract, from May 2021, with the Provincial Health Authority to provide remote patient monitoring to patients throughout the province until September 30, 2023.
The award-winning Cloud DX Connected Health platform monitors and reports on physiological data including heart and respiratory rate, blood pressure, oxygen saturation, weight, temperature and blood glucose levels, along with condition-specific surveys and connection to the patient via two-way messaging and video visits.
Remote patient monitoring and virtual care are used to better engage patients in their care. Cloud DX software issues notifications to a care team if a patient's vital signs, symptoms or adherence to scheduled readings changes. The care team can then trigger a telemedicine video visit to determine the best next step. Early intervention can result in reduced ER visits, avoided hospital admissions and better care outcomes, resulting in a lower overall cost to the healthcare system.
Under the terms of the contract and extension with the province, Cloud DX receives an upfront payment for each Connected Health Kit delivered to a patient, and then charges a monthly connectivity, software and service fee for each active patient account.
About Cloud DX
Accelerating virtual healthcare, Cloud DX is on a mission to make healthcare better for everyone. Our Connected Health TM remote patient monitoring platform is used by healthcare enterprises and care teams across North America to virtually manage chronic disease, enable aging in place, and deliver hospital-quality post-surgical care in the home. Our partners achieve better healthcare and patient outcomes, reduce the need for hospitalization or re-admission, and reduce healthcare delivery costs through more efficient use of resources. Cloud DX is the co-winner of the Qualcomm Tricorder XPRIZE, a 2021 Edison Award winner, a Fast Company "World Changing Idea" finalist, and was named a "New Innovator 2022" by Canadian Business magazine. Cloud DX is an exclusive virtual care partner to Medtronic Canada and Equitable Life.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Click here to connect with Cloud DX (TSX.V:CDX) (OTCQX:CDXFF) to receive an Investor Presentation.
Developing the Clinic of the Future, Cloud DX work to be supported by Sheridan College through federal grant
News in Summary
Cloud DX (TSXV:CDX) (OTCQB:CDXFF), leading Virtual Care platform provider, will partner with Sheridan College (the grant recipient) on a project with Cloud XR, the company's eXtended Reality division, to further develop the Clinic of the Future, an augmented reality (AR) platform. This is made possible through the support of a Natural Sciences and Engineering Research Council (NSERC) Applied Research and Technology Partnership (ARTP) non-dilutive funding grant. As a key industry partner, Cloud DX will work with Sheridan College who will conduct a portfolio of applied research projects in Mobile Health and Health and Machine Learning
Cloud XR's Clinic of the Future demonstrates how its patented Vitaliti™ continuous monitoring device displays real-time patient information in the form of 3-D holographic images. The Clinic of the Future is the Medical Metaverse in action, a fully remote, touchless, seamless method enabling healthcare professionals to interact with patients.
Dr. Sonny Kohli, Chief Medical Officer and Co-Founder at Cloud DX states: "Improving healthcare is important to everyone, we all use it throughout our lives, and advancement in healthcare and medicine is only possible through innovation. Working with partners such as Sheridan's Center for Mobile Innovation is essential to push the industry into the future. At Cloud DX working with leaders such Dr. Edward Sykes helps bring our inventions to life and supports our commercialization of new healthcare devices, such as our patented Vitaliti™. This NSERC funding not only recognizes Canadian technology leadership like our partnership, more importantly it advances the MedTech industry - one where virtual and remote care, AI, and Augmented Reality are embedded throughout; the Medical Metaverse. Think about it, a leading specialist can now examine a patient on the other side of the world, its limitless. The Medical Metaverse will improve access to healthcare, create more efficiencies, lead to better patient outcomes, and much more."
About the Sheridan Centre for Mobile Innovation
The Sheridan Centre for Mobile Innovation (CMI) creates innovative solutions to industry-relevant challenges, in close collaboration with industry, community, and academic partners. CMI uses leading technologies in its research including: mobile, Artificial Intelligent/Machine Learning/Deep Learning, wearable computing, augmented/virtual reality/mixed reality and Internet of Things. Please visit: cmi.sheridancollege.ca. For more information on research and innovation at Sheridan, please visit research.sheridancollege.ca.
About Cloud DX
Accelerating virtual healthcare, Cloud DX is on a mission to make healthcare better for everyone. Our Connected Health TM remote patient monitoring platform is used by healthcare enterprises and care teams across North America to virtually manage chronic disease, enable aging in place, and deliver hospital-quality post-surgical care in the home. Our partners achieve better healthcare and patient outcomes, reduce the need for hospitalization or re-admission, and reduce healthcare delivery costs through more efficient use of resources. Cloud DX is the co-winner of the Qualcomm Tricorder XPRIZE, a 2021 Edison Award winner, a Fast Company "World Changing Idea" finalist, and was named a "New Innovator 2022" by Canadian Business magazine. Cloud DX is an exclusive virtual care partner to Medtronic Canada and Equitable Life.
Cloud DX Investor Sitehttps://ir.clouddx.com/overview/default.aspx
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
# # #
For media inquiries please contact:
Janine Scott
Marketing Lead
888-543-0944
janine.scott@CloudDX.com
For investor inquiries please contact:
Jay Bedard
Cloud DX Investor Relations
647-881-8418
jay.bedard@CloudDX.com
SOURCE:Cloud DX Inc.
News Provided by ACCESSWIRE via QuoteMedia
Cloud DX chosen as Virtual Care Platform for the Ontario Paramedical Service provider, replacing existing hardware and services
Cloud DX (TSXV:CDX)(OTCQX:CDXFF) is pleased to announce a new 24-month contract with an Ontario Paramedic Service Provider enabling the client to provide Remote Patient Monitoring (RPM) across its serviceable area. Cloud DX will provide its award-winning Connected Health™ platform and support the client as it transitions from its previous remote care tools to Cloud DX's Virtual Care Platform. The client showcases how beneficial ‘Remote Care Monitoring' is for Paramedical Service providers, enabling providers to establish deeper community roots and maintain funding levels, while community members benefit from greater access to much-needed care. The client has purchased 223 Connected Health™ kits totalling ~$145,000 CAD with additional recurring fees for subscription software services. Funding for the program comes from the $82.5M Community Paramedicine for Long-Term Care program announced by the Ontario government on October 22, 2021
The Paramedical client will provide Cloud DX's biometric monitoring equipment to clients in their homes to monitor vital signs including weight, blood pressure, heart rate, oxygen level, temperature, and blood glucose. Daily monitoring allows the client and health care providers to make informed decisions and enables the Paramedic to connect with the client if a metric is out of range. The paramedical care provider seeks to keep individuals on the long-term care bed waitlist and individuals who are medically complex or isolated comfortable and safe in their homes. In turn, Remote Care Monitoring is expected to reduce 911 calls, emergency room visits, and hospital admissions.
Cloud DX COO and co-founder, Anthony Kaul, states "At-home remote monitoring is critical to improving the health of vulnerable populations, such as community members with chronic conditions or seniors who wish to live independently for as long as possible. By bringing Remote Care Monitoring directly to the community our client is forging a new path in paramedicine. This modern approach improves community health and enables significantly earlier intervention for those with deteriorating health, in turn reducing hospitalizations. Cloud DX is well known for our high user satisfaction ratings, so we are confident this initiative will be well received by the community. Of course, with our Headquarters in Ontario, we're always extremely happy to support our neighbouring communities."
About Cloud DX
Accelerating virtual healthcare, Cloud DX is on a mission to make healthcare better for everyone. Our Connected Health TM remote patient monitoring platform is used by healthcare enterprises and care teams across North America to virtually manage chronic disease, enable aging in place, and deliver hospital-quality post-surgical care in the home. Our partners achieve better healthcare and patient outcomes, reduce the need for hospitalization or re-admission, and reduce healthcare delivery costs through more efficient use of resources. Cloud DX is the co-winner of the Qualcomm Tricorder XPRIZE, a 2021 Edison Award winner, a Fast Company "World Changing Idea" finalist, and was named a "New Innovator 2022" by Canadian Business magazine. Cloud DX is an exclusive virtual care partner to Medtronic Canada and Equitable Life.
Cloud DX Investor Sitehttps://ir.clouddx.com/overview/default.aspx
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Social Links
Twitter https://twitter.com/CloudDX
Facebook https://www.facebook.com/clouddxinc/
LinkedIn https://www.linkedin.com/company/cloud-dx/
Instagram https://www.instagram.com/cloud.dx/
For media inquiries please contact:
Janine Scott
Marketing Lead
888-543-0944
janine.scott@CloudDX.com
For investor inquiries please contact:
Jay Bedard
Cloud DX Investor Relations
647-881-8418
jay.bedard@CloudDX.com
SOURCE:Cloud DX Inc.
News Provided by ACCESSWIRE via QuoteMedia
Continued growth in US RPM as partner Maxwell Telecare signs two additional clinics in Illinois
News in Summary
Cloud DX (TSXV:CDX) (OTCQB:CDXFF), Cloud DX, a leading Virtual Care platform in North America, and partner Maxwell Telecare announce two additional new contracts with US based Primary Care practices in Illinois. Under the company's Patient First™ program, the clinics will deploy Connected Health™ to control exacerbations, improve quality of life, and avoid hospital admissions, and ER visits. The participating Maxwell clinics will prescribe the kits under US codes for reimbursed Remote Patient Monitoring and Chronic Care Management, paid for by public and private health insurance. This announcement contributes to a record-setting quarter for Cloud DX bringing the total signed contracts this quarter to 12
Rajani Nair, Deployment Manager at Cloud DX, states "Maxwell Telecare understands the value of RPM and how it improves not only a clinic's return on investment but more importantly improves patient care and patient outcomes. As deployments across their network scale, the Maxwell team seamlessly integrates our Connected Health™ kit as part of their patient offerings, reimbursable in the US for RPM or Chronic Care Management. Given their ease of integration, this partnership has transitioned from establishment to scaling. We look forward to continuing to work with them"
Footnotes:
1. Hajat, C., & Stein, E. (2018). The global burden of multiple chronic conditions: A narrative review. Preventive medicine reports, 12, 284-293. https://doi.org/10.1016/j.pmedr.2018.10.008
About Cloud DX
Accelerating virtual healthcare, Cloud DX is on a mission to make healthcare better for everyone. Our Connected Health TM remote patient monitoring platform is used by healthcare enterprises and care teams across North America to virtually manage chronic disease, enable aging in place, and deliver hospital-quality post-surgical care in the home. Our partners achieve better healthcare and patient outcomes, reduce the need for hospitalization or re-admission, and reduce healthcare delivery costs through more efficient use of resources. Cloud DX is the co-winner of the Qualcomm Tricorder XPRIZE, a 2021 Edison Award winner, a Fast Company "World Changing Idea" finalist, and one of "Canada's Ten Most Prominent Telehealth Providers." In 2021, Cloud DX became an exclusive partner of Medtronic Canada.
Cloud DX Investor Sitehttps://ir.clouddx.com/overview/default.aspx
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
# # #
For media inquiries please contact:
Janine Scott
Marketing Lead
888-543-0944
janine.scott@CloudDX.com
For investor inquiries please contact:
Jay Bedard
Cloud DX Investor Relations
647-881-8418
jay.bedard@CloudDX.com
SOURCE:Cloud DX Inc.
News Provided by ACCESSWIRE via QuoteMedia
Cloud DX Signs New Palliative Contract with Ontario Healthcare Team
Healthcare team to use Connected Health™ kits to provide dignity in care for up to 85 patients
News in Summary
Cloud DX (TSXV:CDX)(OTCQB:CDXFF), a leading Virtual Care platform, signs a contract with a healthcare team in Niagara, Ontario, Canada. The team will use Cloud DX's Connected Health™ kits and software services for up to 85 palliative patients. The 12-month contract will commence deployment this month, adding to Cloud DX's successful quarter and recently announced, industry first patent in vital-sign analysis. Connected Health™ has been deployed for palliative patients by other provinces and territories, including Yukon Health and Social Services, since 2019
"While we're known for our post-surgical and chronic care programs, it is refreshing to work with clinics who are passionate about the extended benefits and applications of RPM. This healthcare team understands RPM and recognizes its many use cases," says Head of Operations, Cara MacDonald. "Making healthcare better means encompassing all stages of life, all stages of illness or conditions. We look forward to paving the palliative healthcare delivery pathway with a clinical leader in Ontario."
Palliative Care Management is the third focus area for Cloud DX, building upon its growing Post-Surgical and Chronic Care Management programs. As the digital healthcare sector grows globally, the company continues to work with care providers to pursue new use cases for virtual care and remote patient monitoring while innovating new care pathways alongside industry-leading partners such as Medtronic Canada and Equitable Life.
About Cloud DX
Accelerating virtual healthcare, Cloud DX is on a mission to make healthcare better for everyone. Our Connected Health TM remote patient monitoring platform is used by healthcare enterprises and care teams across North America to virtually manage chronic disease, enable aging in place, and deliver hospital-quality post-surgical care in the home. Our partners achieve better healthcare and patient outcomes, reduce the need for hospitalization or re-admission, and reduce healthcare delivery costs through more efficient use of resources. Cloud DX is the co-winner of the Qualcomm Tricorder XPRIZE, a 2021 Edison Award winner, a Fast Company "World Changing Idea" finalist, and one of "Canada's Ten Most Prominent Telehealth Providers." In 2021, Cloud DX became an exclusive partner to Medtronic Canada.
Cloud DX Investor Sitehttps://ir.clouddx.com/overview/default.aspx
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Social Links
Twitter https://twitter.com/CloudDX
Facebook https://www.facebook.com/clouddxinc/
LinkedIn https://www.linkedin.com/company/cloud-dx/
Instagram https://www.instagram.com/cloud.dx/
For media inquiries please contact:
Janine Scott
Marketing Lead
888-543-0944
janine.scott@CloudDX.com
For investor inquiries please contact:
Jay Bedard
Cloud DX Investor Relations
647-881-8418
jay.bedard@CloudDX.com
SOURCE:Cloud DX Inc.
News Provided by ACCESSWIRE via QuoteMedia
Cloud DX (TSXV:CDX)(OTCQB:CDXFF), a leading North American provider of virtual care and Remote Patient Monitoring (RPM) solutions, is pleased to announce that it has closed a non-brokered private placement (the "Private Placement") of 260 units (the "Units") of the Corporation at a price of $1,000 per Unit, for gross proceeds of $260,000 (the "Offering"). Each Unit is comprised of (i) a C$1,000 principal amount unsecured convertible debenture (each, a "Debenture") and (ii) 1,430 common share purchase warrants of the Corporation (each, a "Warrant"). The Debentures will mature on January 27, 2025 (the "Maturity Date") and shall bear interest at a simple rate of 10% per annum. The principal amount of the Debentures may be converted at the election of the holder thereof into common shares in the capital of the Company ("Common Shares") at a conversion price of C$0.35 per Common Share (the "Conversion Price") at any time prior to the Maturity Date. Each Warrant entitles the holder thereof to acquire one common share of the Corporation (each, a "Common Share") at a price of C$0.50 per Common Share at any time prior to 4:30 p.m. (Toronto Time) on January 27, 2024
As consideration for services rendered in connection with the Offering, the Corporation paid to certain registered brokers a cash commission in the amount equal to $13,000 (5% of the gross proceeds of the Offering); and (ii) issued to certain registered brokers 37,142 non-transferable common share purchase warrants (the "Broker Warrants"). Each Broker Warrant entitles the holder thereof to acquire one Common Share at an exercise price of $0.35 per Common Share for a period of 24 months from the date of closing of the Private Placement.
The Corporation intends to use the net proceeds from the Offering for sales, marketing, research and development and working capital requirements.
In accordance with applicable Canadian securities laws, all securities issued pursuant to the Offering will be subject to a four (4) month hold period ending July 19, 2022. The Offering remains subject to final approval from the TSX Venture Exchange.
The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States or to, or for the account or benefit of, U.S. persons absent registration or an applicable exemption from the registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any State in which such offer, solicitation or sale would be unlawful.
About Cloud DX
Accelerating virtual healthcare, Cloud DX is on a mission to make healthcare better for everyone. Our Connected Health TM remote patient monitoring platform is used by healthcare enterprises and care teams across North America to virtually manage chronic disease, enable aging in place, and deliver hospital-quality post-surgical care in the home. Our partners achieve better healthcare and patient outcomes, reduce the need for hospitalization or re-admission, and reduce healthcare delivery costs through more efficient use of resources. Cloud DX is the co-winner of the Qualcomm Tricorder XPRIZE, a 2021 Edison Award winner, a Fast Company "World Changing Idea" finalist, and one of "Canada's Ten Most Prominent Telehealth Providers." In 2021, Cloud DX became an exclusive partner to Medtronic Canada.
Cloud DX Investor Sitehttps://ir.clouddx.com/overview/default.aspx
Social Links
Twitter https://twitter.com/CloudDX
Facebook https://www.facebook.com/clouddxinc/
LinkedIn https://www.linkedin.com/company/cloud-dx/
Instagram https://www.instagram.com/cloud.dx/
For media inquiries please contact:
Janine Scott
Marketing Lead
888-543-0944
janine.scott@CloudDX.com
For investor inquiries please contact:
Jay Bedard
Cloud DX Investor Relations
647-881-8418
jay.bedard@CloudDX.com
Forward-Looking Information
This news release contains forward-looking statements and information within the meaning of applicable securities legislation. Often, but not always, forward-looking statements and information can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking statements or information involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Corporation to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements or information contained in this news release. In particular, this news release includes certain forward-looking statements concerning the Offering, including the use of the net proceeds, as well as management's objectives, strategies, beliefs and intentions.
Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. In making the forward-looking statements in this news release, the Corporation has applied several material assumptions, including without limitation, information concerning the receipt of approval from the TSX Venture Exchange, the use of proceeds and the Corporation's marketing and research and development strategies and the expected benefits thereof.
Although management of the Corporation has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information.
The securities of the Corporation have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act") or any U.S. state securities laws and may not be offered or sold in the United States absent registration or an available exemption from the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there by any sale of the securities referenced in this press release, in any jurisdiction in which such offer, solicitation or sale would be unlawful.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE:Cloud DX Inc.
News Provided by ACCESSWIRE via QuoteMedia
Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") is pleased to announce that the now complete findings from our previously announced pre-clinical breast cancer and melanoma efficacy studies have been published in the peer-reviewed scientific journal, Frontiers in Immunology. This research article includes new follow-up data which provides a comprehensive analysis of the immunity activated by Sona's Targeted Hyperthermia Therapy ("THT"). The published manuscript titled, "Targeted Intra-tumoral Hyperthermia with Uniquely Biocompatible Gold Nanorods Induces a Strong Immunogenic Cell Death in Two Immunogenically 'Cold' Tumors" is available online in electronic form (here) and will be in print in its upcoming issue of Frontiers in Immunology - Cancer Immunology and Immunotherapy. Frontiers in Immunology is a leading journal in its field, publishing rigorously peer-reviewed research across basic, translational and clinical immunology.
Sona's proprietary, innovative technology uses the Company's patented, biocompatible gold nanorods ("GNRs") to deliver precision, targeted, non-destructive hyperthermia therapy directly to cancers, thereby alleviating the systemic toxicity associated with most other cancer therapies. In this study, Sona's team confirmed that its therapy causes cancer-specific cell death that activates a strong immune response by the body's immune system. Of critical importance in Sona's publication is the evidence that the 'novel immunity' generated by Sona's THT is observed in cancers that are known to be completely resistant to modern immunotherapies.
Sona's Chief Medical Officer, and the manuscript's senior author, Dr. Carman Giacomantonio, commented, "I am extremely proud of my research team lead by Dr. Barry Kennedy, and the quality of the research we have produced. To be published in such a highly respected and rigorously peer-reviewed journal as Frontiers in Immunology is no small feat! In our studies, we've shown in industry standard, pre-clinical cancer models that Sona's therapy can eliminate cancers by converting them from 'cold', immune unresponsive tumors, into 'hot' immunogenic tumors. In the many years I have been involved in cancer research and treatment, I have never seen a treatment trigger such a powerful immune response in otherwise 'cold' tumors and our data makes it clear that there was no meaningful immune response to standard immunotherapies without THT in these studies. Our publication in Frontiers in Immunology elevates our findings to an international level, giving us new audience with other leading cancer research laboratories and potential industry partners. Most importantly, this publication provides us with 'proof-of-concept', supporting the clinical trial protocols we are striving to launch in 2025."
"Our research appearing in a leading scientific journal is evidence of Sona delivering on our commitment to build a 'mountain of data' that will support our planned regulatory filings. Its findings motivate our team to press on, affirming our conviction that THT- immunotherapy will be highly effective in the clinical setting. While we continue to conduct research on other cancers, we are now also focused on delivering evidence through first-in-human clinical trials, both here and abroad, as quickly as possible. This peer-reviewed publication of successful treatment using Sona's THT in melanoma and breast cancers provides the credibility necessary to help make that happen," said David Regan, Chief Executive Office of Sona Nanotech.
Contact:
David Regan, CEO
+1-902-442-0653
david@sonanano.com
About Sona Nanotech Inc.
Sona Nanotech is developing Targeted Hyperthermia™, a photothermal cancer therapy, which uses therapeutic heat to treat solid cancer tumors. The heat is delivered to tumors by infrared light that is absorbed by Sona's gold nanorods in the tumor and re-emitted as heat. Therapeutic heat (42-48°C) stimulates the immune system, shrinks tumors, inactivates cancer stem cells, and increases tumor perfusion - thus enabling drugs to reach all tumor compartments more effectively. Targeted Hyperthermia promises to be safe, effective, minimally invasive, competitive in cost, and a valuable adjunct to drug therapy and other cancer treatments.
Sona has developed multiple proprietary methods for the manufacture of gold nanoparticles which it uses for the development of both cancer therapies and diagnostic testing platforms. Sona Nanotech's gold nanorod particles are cetyltrimethylammonium ("CTAB") free, eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications.
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION: This press release includes certain "forward-looking statements" under applicable Canadian securities legislation, including statements regarding the anticipated applications and potential opportunities of Targeted Hyperthermia Therapy, and Sona's preclinical and clinical study plans. Forward-looking statements are necessarily based upon a number of assumptions or estimates that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements, including the risk that Sona may not be able to successfully obtain sufficient clinical and other data to submit regulatory submissions, raise sufficient additional capital, secure patents or develop the envisioned therapy, and the risk that THT may not prove to have the benefits currently anticipated. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. Sona disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Not for distribution to United States newswire services or for dissemination in the United States
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/236960
News Provided by Newsfile via QuoteMedia
Spearmint Resources Inc. (CSE: SPMT) (OTC Pink: SPMTF) (FSE: A2AHL5) (the "Company" or "Spearmint") wishes to announce that it has more than doubled the acreage on the recently acquired George Lake South Antimony Project in New Brunswick, Canada. This project now consists of 4,722 contiguous acres prospective for antimony.
James Nelson, President of Spearmint stated, "In light of the recent ban of antimony by China to the USA, we made this strategic acquisition increasing the size of the George Lake South Antimony Project. Management feels that antimony will be one of the most sought after resources in 2025 and we plan to pursue this space with vigor and are currently evaluating additional projects. Management is formulating a plan on the George Lake South Antimony Project, and management also intends to update the market on Spearmint's crypto diversification plan in the near future as well. These are truly exciting times for Spearmint and Spearmint shareholders."
Recently, China banned exports of critical minerals, including antimony, to the United States. As trade tensions escalate between the United States and China, this move clearly emphasizes the urgent need for Western nations to secure reliable long-term sources of these critical minerals, which are now at the forefront of the global supply chain crisis.
Antimony is an essential component in semi-conductors, battery storage technology, and has several military applications. Prices of antimony trioxide in Rotterdam had soared by 228 per cent since the beginning of the year to $39,000 a metric tonne on Nov. 28, as shown by data from information provider Argus. The move is a considerable escalation of tensions in supply chains where access to raw material units is already tight in the West.
This new project is in the direct vicinity of the Lake George Antimony Mine in New Brunswick which was operated intermittently from 1876 to 1996 and was once the largest primary antimony producer in North America. Antimony's primary uses are:
About Spearmint Resources Inc.
Spearmint holds the include four projects in Clayton Valley, Nevada: the 1,136-acre McGee lithium clay deposit, which has a resource estimate of 1,369,000 indicated tonnes and 723,000 inferred tonnes of lithium carbonate equivalent (LCE) for a total of 2,092,000 tonnes of LCE, directly bordering Pure Energy Minerals & Century Lithium Corp.; the 280-acre Elon lithium brine project, which has access to some of the deepest parts of the only lithium brine basin in production in North America; the 124-acre Green Clay lithium project; and the 248-acre Clayton Ridge gold project and now the 4,722 acre George Lake South Antimony Project in New Brunswick.
For a cautionary note and disclaimer on the crypto diversification, please refer to the news release dated November 12, 2024.
Qualified person for mining disclosure:
The technical contents of this release were reviewed and approved by Frank Bain, PGeo, a director of the company and qualified person as defined by National Instrument 43-101.
This property was acquired via staking.
Contact Information
Tel: 1604646-6903
www.spearmintresources.ca
"James Nelson"
President
Spearmint Resources Inc.
The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/233899
News Provided by Newsfile via QuoteMedia
Tech stocks surged this week as US and Canadian jobs data bolstered interest rate cut expectations.
Broadcom (NASDAQ:AVGO) became the newest member of the trillion-dollar club, crossing the market cap threshold in early trading on Friday (December 13) after a strong earnings forecast caught attention. Meanwhile, its peer NVIDIA (NASDAQ:NVDA) suffered losses as it prepares to face probes in both China and the US.
Meanwhile, Google (NASDAQ:GOOGL) announced a quantum computing milestone, and Tesla (NASDAQ:TSLA) CEO Elon Musk called out the US Securities and Exchange Commission (SEC) over multiple probes into his business dealings.
In crypto news, investors maintained a bullish outlook despite a slight pullback.
Find out what other key pieces of news mead headlines in the tech space this week.
Bitcoin fell below the US$100,000 mark at the start of the week after last's week's record-setting price move. Altcoins and meme tokens also took a hit, hinting at a potential shift in market dynamics.
Some analysts believe Bitcoin is consolidating, with a surge in buying needed to overcome the US$101,000 level. Even so, other experts predict Bitcoin could reach US$120,000 in the coming weeks.
Bitcoin's lowest point for the week came on Tuesday (December 10), when US$1.5 billion in long positions were liquidated. This downturn may have been fueled by concerns over Google's new quantum computing chip, which were later debunked by experts. The cryptocurrency recovered to rise above US$101,000 on Wednesday (December 11) afternoon, and briefly touched US$102,500 on Thursday (December 12). The increase came as traders bought the dip and as Wednesday’s US consumer price index report boosted investor confidence in crypto and tech stocks.
Wall Street also saw impressive gains on Wednesday, with the Nasdaq Composite (INDEXNASDAQ:.IXIC) closing above the 20,000 level for the first time. However, both cryptocurrencies and stocks retreated slightly after Thursday’s US producer price index reading showed producer costs had risen above estimates.
Bitcoin held around US$101,500 on Friday, while Ether was above US$3,900.
Bitcoin and Ether spot exchange-traded funds (ETFs) saw inflows this week, with over US$4 billion entering Bitcoin spot ETFs and over US$1.9 billion going into Ether spot ETFs in the past few days, as per SoSo Value data.
Despite the ongoing bullish sentiment, the Bitcoin-to-gold ratio is showing signs of an imminent correction. The resistance level has been between 34 and 37 since early to-mid November, a point that has been associated with local market tops. Additionally, the Bitcoin Relative Strength Index crossed above 70 in November, indicating overbought conditions — a pattern that has often preceded sharp price declines in the past.
Musk expressed his discontent on X, formerly Twitter, on Thursday regarding a settlement demand issued by the SEC. The demand requires Musk to accept terms, including a fine, or face charges on multiple counts.
In a letter sent to the SEC and posted to X, Musk’s lawyer Alex Spiro accuses the SEC of engaging in “an improperly motivated campaign against Mr. Musk and the individuals and companies associated with him."
In February 2022, the SEC launched an investigation into Musk's business activities due to concerns about potential insider trading. It was based on suspicions that he might have shared confidential information with his brother.
Later, in April 2022, the Oklahoma Firefighters Pension and Retirement System sued Musk, accusing him of deliberately concealing his investments in Twitter and his intent to buy the company.
The fund’s attorneys argued that Musk influenced other shareholders’ decisions and put them at a disadvantage by failing to clearly disclose pertinent information regarding his stake in the company.
Both cases are ongoing at this time. The SEC's settlement demand letter is specifically related to concerns about Musk's disclosures regarding his initial purchase of Twitter shares in 2022.
Spiro's letter also references a reopened investigation into Musk’s biotech company Neuralink; it began in September 2023, when the nonprofit Physicians Committee for Responsible Medicine requested that the commission investigate the company for securities fraud after Musk falsely claimed that “no monkey has died as a result of a Neuralink implant.” The group claims that Musk lied to investors about the safety of the device.
Sources for CNBC said charges may not immediately follow if the SEC is unable to settle with Musk. Rather, SEC staff may issue a Wells notice before commissioners decide whether to file formal charges.
The news came as Musk's net worth passed US$400 billion, buoyed by Tesla and SpaceX valuations.
Broadcom released results for its fourth fiscal quarter and full 2024 year on Thursday, revealing a 51 percent year-on-year revenue increase for Q4 and an 11 percent rise in its common stock dividend from the prior quarter.
The company also reported GAAP net income of US$4,324 million for the fourth quarter, non-GAAP net income of US$6,965 million and adjusted EBITDA of US$9.01 million for Q4.
Looking forward, Broadcom estimates that it could derive US$90 billion in revenue from custom artificial intelligence (A) chips by 2027, driven by key customers like Google and Meta (NASDAQ:META). There is potential for significant expansion if contracts with Microsoft (NASDAQ:MSFT) or Amazon (NASDAQ:AMZN) are secured.
Broadcom's strong outlook has spurred optimism among analysts at Jefferies Financial Group (NYSE:JEF), Morgan Stanley (NYSE:MS) and Evercore (NYSE:EVR), sparking a rally that sent its share price soaring over 24 percent to a new all-time high of US$224 on Friday, culminating in a market cap of US$1.05 trillion.
This positive sentiment extended to other chip stocks, with Marvell Technology (NASDAQ:MRVL), Micron Technology (NASDAQ:MU) and Taiwan Semiconductor Manufacturing (NYSE:TSM) also experiencing gains. The PHLX Semiconductor Sector (INDEXNASDAQ:SOX) closed up 3.36 percent for the day and 1.57 percent for the week.
Ahead of Broadcom’s results, Bloomberg reported on Thursday that Apple (NASDAQ:AAPL) — one of the chipmaker’s biggest customers — is working to replace Broadcom's combined Wi-Fi and Bluetooth chip with its own in-house technology, codenamed Proxima. Taiwan Semiconductor will manufacture the chip, which is reportedly anticipated to be used in products as early as 2025.
Google took a significant quantum computing step with the unveiling of its Willow quantum processor on Monday (December 9). Willow features 105 qubits — fundamental units of information in quantum computing, similar to bits in classical computers — and demonstrates a significant reduction in error rates as the number of qubits increases.
This addresses a major challenge in quantum computing, where qubits are highly susceptible to environmental interference. Willow also excels in random circuit sampling, a benchmark test that involves running a quantum computer with a series of random operations and then measuring the output. According to Google, Willow can complete a calculation in under 5 minutes that would have taken the fastest supercomputer 10 septillion years.
Some commentators, including Andy Parackal, an AI and machine learning advocate and the founder of Parackal Coaching, came forward to express concerns that Willow’s quantum computing abilities could be enough to crack Bitcoin’s cryptographic hash function, Secure Hash Algorithm 256-bit. However, industry experts like Cinemad Producer have said these concerns are unfounded because Willow is not yet powerful enough. Willow has reached 105 qubits with improved error rates, but 2022 research from Universal Quantum and the University of Sussex shows that a quantum computer with a capacity of 1.9 billion qubits would be required to break Bitcoin's encryption.
Willow's advancements represent a significant step forward in quantum computing, offering the potential to revolutionize various fields, including drug discovery, materials science and AI.
Google also released Gemini 2.0, its most advanced multimodal AI model to date, to developers and testers on Wednesday. According to the company, Gemini 2.0 will be capable of generating images and audio, with a focus on enhancing "agentic experiences" across applications.
Google DeepMind CEO Demis Hassabis and CTO Koray Kavukcuoglu said in a joint statement that AI agents powered by Gemini 2.0 will be able to understand complex instructions, plan, reason and even assist with video game strategy.
A full release is slated for next year, but in the meantime, Gemini Advanced users will be able to try out the chat-optimized version of Gemini 2.0 within the Gemini app.
NVIDIA's share price dropped 2.5 percent on Monday following the news that China's market regulator will be investigating potential violations of the country's antimonopoly law.
The investigation is reportedly focused on the terms of NVIDIA's 2020 acquisition of Mellanox Technologies, an Israeli-American company that specialized in high-performance interconnect solutions prior to the purchase.
NVIDIA is currently facing legal challenges on multiple fronts. In the US, a class-action lawsuit alleging that the company misled investors about the connection between its sales and cryptocurrency mining has been allowed to proceed by the Supreme Court. The Associated Press released the news on Wednesday.
Shares of NVIDIA are down 3.27 percent for the week, dwarfed by the gains of competitor Broadcom.
Don't forget to follow us @INN_Technology for real-time news updates!
Securities Disclosure: I, Meagen Seatter, hold no direct investment interest in any company mentioned in this article.
The US Securities and Exchange Commission (SEC) has reopened its investigation into Neuralink, Elon Musk’s brain-implant company, alongside a probe into Musk’s acquisition of Twitter, now rebranded as X.
A letter from Musk’s lawyer, Alex Spiro, disclosed the development on Thursday (December 12), raising questions about the ongoing legal disputes between Musk and the SEC, according to a Reuters report.
The letter, addressed to outgoing SEC Chair Gary Gensler, outlines the reopening of the Neuralink investigation and a settlement demand regarding the Twitter takeover, which happened in 2022.
The SEC has reportedly issued Musk a 48 hour deadline to accept a settlement offer or face enforcement action.
Details about the settlement amount have not been disclosed, and the SEC has yet to comment on the matter, citing its confidentiality policy regarding investigations.
The SEC’s investigation into Neuralink adds another layer to Musk’s longstanding conflicts with the agency.
While the exact nature of the Neuralink probe remains unclear, Musk’s acquisition of Twitter over two years ago has been under scrutiny due to the timing and disclosure of his stock purchases.
Musk began acquiring Twitter shares in early 2022, eventually reaching a 9 percent stake before announcing plans to buy the social media platform outright for US$44 billion.
The letter accuses the SEC of harassment, referencing prior legal battles between Musk and the commission.
In 2018, Musk faced a lawsuit from the SEC over a tweet claiming he had secured funding to take Tesla private.
That case was resolved with a US$20 million fine; Musk also had to step down as Tesla’s chairman, and Tesla lawyers were required to review some of his public statements.
In his letter to the SEC, Spiro criticizes the government body's actions, questioning the motivation behind the investigations and alleging that they were politically influenced. The lawyer also demands transparency about whether Gensler or other government entities have been directing what Spiro calls a campaign against Musk.
Neuralink, which was founded by Musk in 2016, aims to develop brain-computer interfaces with potential applications in medical treatment and human enhancement.
The company has faced challenges, including public and legal scrutiny over its research practices.
In 2023, the Physicians Committee for Responsible Medicine and four US lawmakers urged the SEC to investigate Neuralink for possible securities fraud, alleging that the company made misleading claims about its technology.
Musk has frequently expressed disdain for the SEC in the past. Following the publication of Spiro’s letter, he posted an image mocking Gensler on X, accompanied by a dismissive caption.
The investigation comes at a crucial time for Musk as his influence expands.
He is a member of a task force established by President-elect Donald Trump to oversee government reforms, and spent significant resources supporting Trump’s political campaign.
In November, a federal judge denied an SEC request to impose sanctions on Musk for failing to comply with court-ordered testimony related to the Twitter acquisition probe. Currently the outcome of the reopened Neuralink investigation and the ongoing Twitter acquisition probe remains uncertain.
Don’t forget to follow us @INN_Technology for real-time updates!
Securities Disclosure: I, Giann Liguid, hold no direct investment interest in any company mentioned in this article.
Spearmint Resources Inc. (CSE: SPMT) (OTC Pink: SPMTF) (FSE: A2AHL5) (the "Company" or "Spearmint") wishes to announce that it has more than doubled the acreage on the recently acquired George Lake South Antimony Project in New Brunswick, Canada. This project now consists of 4,722 contiguous acres prospective for antimony.
James Nelson, President of Spearmint, stated, "In light of the recent ban of antimony by China to the USA, we made this strategic acquisition increasing the size of the George Lake South Antimony Project. Management feels that antimony will be one of the most sought after resources in 2025 and we plan to pursue this space with vigor and are currently evaluating additional projects. Management is formulating a plan on the George Lake South Antimony Project, and management also intends to update the market on Spearmint's crypto diversification plan in the near future as well. These are truly exciting times for Spearmint and Spearmint shareholders."
Recently, China banned exports of critical minerals, including antimony, to the United States. As trade tensions escalate between the United States and China, this move clearly emphasizes the urgent need for Western nations to secure reliable long-term sources of these critical minerals, which are now at the forefront of the global supply chain crisis.
Antimony is an essential component in semi-conductors, battery storage technology, and has several military applications. Prices of antimony trioxide in Rotterdam had soared by 228 per cent since the beginning of the year to $39,000 a metric tonne on Nov. 28, as shown by data from information provider Argus. The move is a considerable escalation of tensions in supply chains where access to raw material units is already tight in the West.
This new project is in the direct vicinity of the Lake George Antimony Mine in New Brunswick which was operated intermittently from 1876 to 1996 and was once the largest primary antimony producer in North America. Antimony's primary uses are:
About Spearmint Resources Inc.
Spearmint holds the include four projects in Clayton Valley, Nevada: the 1,136-acre McGee lithium clay deposit, which has a resource estimate of 1,369,000 indicated tonnes and 723,000 inferred tonnes of lithium carbonate equivalent (LCE) for a total of 2,092,000 tonnes of LCE, directly bordering Pure Energy Minerals & Century Lithium Corp.; the 280-acre Elon lithium brine project, which has access to some of the deepest parts of the only lithium brine basin in production in North America; the 124-acre Green Clay lithium project; and the 248-acre Clayton Ridge gold project and now the 4,722 acre George Lake South Antimony Project in New Brunswick.
For a cautionary note and disclaimer on the crypto diversification, please refer to the news release dated November 12, 2024.
Qualified person for mining disclosure:
The technical contents of this release were reviewed and approved by Frank Bain, PGeo, a director of the company and qualified person as defined by National Instrument 43-101.
This property was acquired via staking.
Contact Information
Tel: 1-604-646-6903
www.spearmintresources.ca
"James Nelson"
President
Spearmint Resources Inc.
The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/233645
News Provided by Newsfile via QuoteMedia
Spearmint Resources Inc. (CSE: SPMT) (OTC Pink: SPMTF) (FSE: A2AHL5) (the "Company" or "Spearmint") wishes to provide an update to shareholders on the impact of the strike by the Canadian Union of Postal Workers on the Company's ability to comply with its obligations to deliver to shareholders its financial statements and related disclosure and proxy-related materials in respect of the Company's annual general meeting of shareholders (the "Meeting") scheduled to be held at Cozen O'Connor LLP - 550 Burrard Street, Suite 2501, Vancouver, B.C., on Thursday, Dec. 19, 2024, at 10 a.m. PST.
James Nelson, President of Spearmint stated, "We want all of our shareholders to be aware of the current situation as there are many exciting events occurring for Spearmint in the short and medium term."
As a result of the strike and pursuant to Canadian Securities Administrators' Co-ordinated Blanket Order 51-931 (Temporary Exemption) from requirements in National Instrument 51-102 (Continuous Disclosure Requirements) and National Instrument 54-101 (Communication with Beneficial Owners of Securities of a Reporting Issuer) to send certain proxy-related materials during a postal strike, the Company is advising shareholders that:
About Spearmint Resources Inc.
Spearmint's projects include four projects in Clayton Valley, Nevada: the 1,136-acre McGee lithium clay deposit, which has a resource estimate of 1,369,000 indicated tonnes and 723,000 inferred tonnes of lithium carbonate equivalent (LCE) for a total of 2,092,000 tonnes of LCE, directly bordering Pure Energy Minerals & Century Lithium Corp.; the 280-acre Elon lithium brine project, which has access to some of the deepest parts of the only lithium brine basin in production in North America; the 124-acre Green Clay lithium project; and the 248-acre Clayton Ridge gold project and now the 1,945 acres George Lake South Antimony Project in New Brunswick.
Contact Information
Tel: 1604646-6903
www.spearmintresources.ca
"James Nelson"
President
Spearmint Resources Inc.
The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/233566
News Provided by Newsfile via QuoteMedia
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.